0000950170-24-060452.txt : 20240515 0000950170-24-060452.hdr.sgml : 20240515 20240515161016 ACCESSION NUMBER: 0000950170-24-060452 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240515 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Athira Pharma, Inc. CENTRAL INDEX KEY: 0001620463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 453368487 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39503 FILM NUMBER: 24950668 BUSINESS ADDRESS: STREET 1: 18706 NORTH CREEK PARKWAY, SUITE 104 CITY: BOTHELL STATE: WA ZIP: 98011 BUSINESS PHONE: (425) 620-8501 MAIL ADDRESS: STREET 1: 18706 NORTH CREEK PARKWAY, SUITE 104 CITY: BOTHELL STATE: WA ZIP: 98011 FORMER COMPANY: FORMER CONFORMED NAME: M3 Biotechnology, Inc. DATE OF NAME CHANGE: 20140924 8-K 1 atha-20240515.htm 8-K 8-K
0001620463false00016204632024-05-152024-05-15

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2024

 

Athira Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-39503

45-3368487

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

18706 North Creek Parkway, Suite 104
Bothell, WA 98011

(Address of principal executive offices, including zip code)

 

(425) 620-8501

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

ATHA

The Nasdaq Stock Market LLC 
(The Nasdaq Global Select Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).

 

 

 

 


 

Item 2.02 Results of Operations and Financial Condition.

On May 15, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s website (www.athira.com), its investor relations website (investors.athira.com), and its news site (investors.athira.com/news-and-events/press-releases). The Company uses these channels, as well as social media, including its X account (formerly known as Twitter)(@athirapharma), LinkedIn account (www.linkedin.com/company/athirapharma), Instagram account (@athirapharma) and Facebook page (www.facebook.com/athirapharmainc), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

 

Description

99.1

 

Athira Pharma, Inc. press release dated May 15, 2024

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL)

 

The information furnished in this Current Report under Items 2.02 and 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

Athira Pharma, Inc.

 

 

 

 

Date:

May 15, 2024

By:

/s/ Mark Litton

 

 

 

Mark Litton

 

 

 

President and Chief Executive Officer

 

 

 

 


EX-99.1 2 atha-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

img247042425_0.jpg 

 

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

 

Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease expected in second half of 2024

Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024

 

Strong balance sheet to support innovative pipeline through key clinical inflection points

 

BOTHELL, Wash., May 15, 2024 – Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.

 

“We are on the cusp of a potentially transformative milestone as we are fast approaching the expected topline data readout from our Phase 2/3 LIFT-AD clinical trial of fosgonimeton in Alzheimer’s disease (AD) in the second half of this year,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. “The totality of clinical and nonclinical data to date support our confidence in the LIFT-AD trial and underscore the potential of our differentiated approach in targeting the neurotrophic HGF system to induce neuroprotective effects across a number of neurodegenerative diseases.”

 

“We were delighted to welcome Javier San Martin, M.D. as our new Chief Medical Officer. His insight and expertise will be invaluable as we move toward the LIFT-AD data readout and the potential opportunity to deliver fosgonimeton as a new treatment option for AD patients in need of better therapies. In parallel, we continue to progress ATH-1105 in amyotrophic lateral sclerosis (ALS) and expect to initiate a first-in-human study of this oral small molecule drug candidate in the coming months,” added Dr. Litton.

Clinical Development & Pipeline Programs

 

Athira’s drug development pipeline includes potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule drug candidates designed to promote the neurotrophic hepatocyte growth factor (HGF) system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system. Athira’s drug candidates have distinct properties, which the Company believes may be applicable to a broad range of neurodegenerative diseases.


 

Fosgonimeton (ATH-1017) – A potentially first-in-class, once daily, subcutaneously administered drug candidate initially targeted for the potential treatment of Alzheimer’s disease.

LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (NCT04488419)

 

Athira expects to report topline data from LIFT-AD in the second half of 2024.
In January 2024, Athira announced the completion of enrollment of the LIFT-AD study.
The LIFT-AD study is investigating the effects of fosgonimeton 40 mg compared with placebo in mild-to-moderate AD patients who are not receiving background therapy. The primary endpoint is the Global Statistical Test (GST), combining the results from the co-key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23), which Athira believes is a comprehensive measure of overall disease burden. Other secondary and exploratory endpoints include changes in plasma biomarkers of neurodegeneration, protein pathology, and neuroinflammation.

Open Label Extension (OLEX) fosgonimeton trial (NCT04886063)

 

Eligible participants who complete the Company’s LIFT-AD or ACT-AD clinical trials and elect to participate in the ongoing OLEX are able to receive up to 48 months of open-label treatment.
Greater than 85% of participants who completed either study have elected to enroll in OLEX to date.
Currently, more than 65 patients are continuing fosgonimeton treatment beyond 18 months, which is unexpected in a progressive mild-to-moderate Alzheimer’s disease population.
Athira believes the OLEX will complement its long-term safety database and provide insights into fosgonimeton’s long-term effects for potentially over four years of investigational treatment.

 

SHAPE Phase 2 clinical trial of fosgonimeton in Parkinson’s disease dementia and dementia with Lewy bodies (NCT04831281)

 

In December 2023, Athira announced encouraging findings from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.
Treatment with fosgonimeton 40 mg (n=5) compared to placebo (n=7) showed directional improvements in certain cognitive, functional and biomarker measurements, including ADAS-Cog13, MMSE, and COWAT over the 6-month double-blind treatment period.
The primary endpoint of the trial, a composite score of the change in Event-Related-Potential (ERP) P300 latency and cognitive assessment (ADAS-Cog13), was not met by protocoled analysis compared with placebo.
Fosgonimeton was generally well tolerated, with a favorable safety profile. There were no treatment-related serious adverse events observed in the study. The most common adverse event in the treatment groups was injection site reactions.


 

ATH-1105 – A next-generation, orally administered, small molecule drug candidate in development for the potential treatment of ALS.

 

Athira submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for the evaluation of ATH-1105 as a potential treatment for ALS.
Athira expects to initiate a first-in-human study of ATH-1105 in the second quarter of 2024.
ATH-1105’s potential is supported by a growing body of preclinical evidence demonstrating statistically significant improvements on nerve and motor function, biomarkers of inflammation and neurodegeneration, and survival in various models of ALS.
These data have been presented at a variety of key scientific and medical meetings including the American Association of Neurology (AAN), the Alzheimer’s Association International Congress (AAIC), the Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS), and the Motor Neurone Disease Association (MNDA).

Corporate

In April 2024, the Company announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin is an experienced clinical development executive with a strong track record of advancing therapeutics from early development to approval and through commercialization. He joins Athira with more than 25 years of drug development experience, most recently as Chief Medical Officer of Arrowhead Pharmaceuticals.

 

Recent Presentations and Publications

In April 2024, Athira presented a poster at the American Academy of Neurology (AAN) 2024 Annual Meeting, which highlighted preclinical data supporting the continued development of its small molecule candidates targeting the neurotrophic HGF system. The presentation was titled: “Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders.”
In April 2024, Athira published preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s disease in the peer-reviewed journal, Neurotherapeutics. The original research article is titled: “Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer’s disease.”
o
The findings described several mechanisms by which fosgonimeton may disrupt the neurodegenerative cascade of Alzheimer’s disease downstream of Aβ toxicity, including reduction of mitochondrial oxidative stress and excitotoxicity, improvement of autophagic pathway function, and attenuation of tau hyperphosphorylation.
In March 2024, Athira presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders.
o
Results from the exploratory SHAPE Phase 2 clinical trial in Parkinson’s disease dementia and dementia with Lewy bodies indicated a favorable safety and tolerability profile for fosgonimeton in trial participants. In addition, changes in ADAS-Cog13 observed in the fosgonimeton 40 mg dose arm were suggestive of a pro-cognitive effect, which was assessed for fosgonimeton for the first time in these disease states.
o
In Alzheimer’s preclinical disease models, results showed the neuroprotective effects of fosgonimeton against glutamate toxicity in vitro are driven, in part, by activation of pro-survival signaling pathways that may help to counteract neurodegenerative hallmarks of disease such as tau pathology and mitochondrial dysfunction.

 

o
In Parkinson’s preclinical disease models, results highlighted the ability of fosgonimeton to mitigate pathological alterations associated with α-synuclein toxicity in vitro and in vivo.
o
In an aged mouse preclinical model of Parkinson’s disease that included α-synuclein pathology and GBA1 inhibition, fosgonimeton improved motor function, promoted dopaminergic neuron survival, reduced α-synuclein aggregation, and protected against microglial activation.
In February 2024, Athira published research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of ALS in the peer-reviewed journal, Frontiers in Neuroscience. The original research article is titled: “ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS.”
All presentations and publications can be accessed on the Athira website at Medical Affairs – Athira Pharma.

Financial Results

Cash Position. Cash, cash equivalents and investments were $122.1 million as of March 31, 2024, compared to $147.4 million as of December 31, 2023. Net cash used in operations was $25.8 million for the quarter ended March 31, 2024, compared to $26.2 million for the quarter ended March 31, 2023.
 
Research and Development (R&D) Expenses. R&D expenses were $21.2 million for the quarter ended March 31, 2024, compared to $21.3 million for the quarter ended March 31, 2023. The decrease was driven primarily by decreases in ATH-1020 program costs and personnel costs, partially offset by an increase in other indirect costs. Fosgonimeton program costs for the quarter ended March 31, 2024, were flat compared to the quarter ended March 31, 2023, as decreases in manufacturing and contract research organization costs were offset by increases in program consulting expenses and clinical site visit costs.
 
General and Administrative (G&A) Expenses. G&A expenses were $6.5 million for the quarter ended March 31, 2024, compared to $8.5 million for the quarter ended March 31, 2023. The decrease was driven by decreases in legal costs, business development expenses, professional services expenses, personnel costs, and other general corporate expenses.

 

Net Loss. Net loss was $26.3 million, or $0.69 per share, for the quarter ended March 31, 2024, compared to a net loss of $27.8 million, or $0.73 per share, for the quarter ended March 31, 2023.

 

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of drug candidates that modulate the neurotrophic HGF system. For more information, visit
www.athira.com. You can also follow Athira on Facebook, LinkedIn, X (formerly known as Twitter) and Instagram.

 


 

Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: Athira’s drug candidates as potential treatments for Alzheimer’s disease, Parkinson’s disease, Parkinson’s disease dementia, dementia with Lewy bodies, amyotrophic lateral sclerosis, and other neurodegenerative diseases; future development plans; the anticipated reporting of data; the potential learnings from preclinical studies and other nonclinical data, the ACT-AD and SHAPE trials, and LIFT-AD unblinded interim efficacy and futility analysis and their ability to inform and improve future clinical development plans; expectations regarding the potential efficacy and commercial potential of Athira’s drug candidates; and Athira’s ability to advance its drug candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “on track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,” “continue,” “suggest,” “potential,” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira’s drug candidates; development of drug candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for drug candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's drug candidates with other treatments; Athira’s assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; the impact of expanded drug candidate development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira’s filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

 

Investor & Media Contact:

Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

 

 

 


 

Athira Pharma, Inc.

Condensed Consolidated Balance Sheets

(Amounts in thousands)

 

 

March 31,

 

December 31,

2024

2023

 

 

(unaudited)

 

 

 

 

Assets

  Cash and cash equivalents

$

77,821

$

90,584

  Short-term investments

44,267

56,835

  Other short-term assets

6,548

7,310

  Other long-term assets

4,822

5,516

Total assets

$

133,458

$

160,245

Liabilities and stockholders' equity

  Current liabilities

$

25,598

$

28,840

  Long-term liabilities

1,118

1,217

Total liabilities

26,716

30,057

Stockholders' equity

106,742

130,188

Total liabilities and stockholders' equity

$

133,458

$

160,245

 

 


 

Athira Pharma, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Amounts in thousands, except share and per share amounts)

(Unaudited)

 

 

Three Months Ended March 31,

2024

2023

Operating expenses:

Research and development

$

21,236

$

21,293

General and administrative

6,451

8,477

Total operating expenses

27,687

29,770

Loss from operations

(27,687

)

(29,770

)

Grant income

157

Other income, net

1,350

1,793

Net loss

$

(26,337

)

$

(27,820

)

Unrealized gain on available-for-sale securities

212

 

927

 

Comprehensive loss attributable to common stockholders

$

(26,125

)

$

(26,893

)

Net loss per share attributable to common stockholders,

   basic and diluted

$

(0.69

)

$

(0.73

)

Weighted-average shares used in computing net loss per

   share attributable to common stockholders, basic

   and diluted

38,321,573

37,923,402

 

 


GRAPHIC 3 img247042425_0.jpg GRAPHIC begin 644 img247042425_0.jpg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end EX-101.SCH 4 atha-20240515.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Entity Central Index Key Entity Tax Identification Number Entity Registrant Name Entity Ex Transition Period Document Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Entity Emerging Growth Company Amendment Flag Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line One Title of 12(b) Security Document Type XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 15, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 15, 2024
Entity Registrant Name Athira Pharma, Inc.
Entity Central Index Key 0001620463
Entity Incorporation, State or Country Code DE
Securities Act File Number 001-39503
Entity Tax Identification Number 45-3368487
Entity Address, Address Line One 18706 North Creek Parkway
Entity Address, Address Line Two Suite 104
Entity Address, City or Town Bothell
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98011
City Area Code 425
Local Phone Number 620-8501
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol ATHA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports atha-20240515.htm atha-20240515.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "atha-20240515.htm": { "nsprefix": "atha", "nsuri": "http://athira.com/20240515", "dts": { "inline": { "local": [ "atha-20240515.htm" ] }, "schema": { "local": [ "atha-20240515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "atha-20240515.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "atha-20240515.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-060452-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-060452-xbrl.zip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end XML 16 atha-20240515_htm.xml IDEA: XBRL DOCUMENT 0001620463 2024-05-15 2024-05-15 0001620463 false 8-K 2024-05-15 Athira Pharma, Inc. DE 001-39503 45-3368487 18706 North Creek Parkway Suite 104 Bothell WA 98011 425 620-8501 false false false false Common Stock, $0.0001 par value per share ATHA NASDAQ true false